Colonic metastases from non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Colonic metastases from non-small cell lung cancer.
A 68-year-old man, heavy smoker, was admitted due a four month history of low back pain, weight loss, fatigue, and worsening constipation. Physical examination was unremarkable. Laboratory studies showed mild anemia and a standard chest X-ray was normal. A spine NMR demonstrated several lytic lesions suggesting metastatic disease. Upper panendoscopy was normal; colonoscopy revealed multiple ulc...
متن کاملLarge bilateral adrenal metastases in non-small cell lung cancer
BACKGROUND The adrenal gland is one of the common sites of metastasis from primary lung cancer. Adrenal metastases are usually unilateral however bilateral adrenal metastases are seen in 10% of all lung cancer patients; of these 2-3% occurs at the initial presentation of non-small cell lung cancer. Secondary tumors can disrupt the structure and function of the adrenal. This can lead to adrenal ...
متن کاملSkip mediastinal nodal metastases in non-small cell lung cancer.
OBJECTIVE To reveal the incidence and clinical significance of mediastinal nodal metastases without N1-station nodal metastases ('skip-N2 metastases') in non-small cell lung cancer (NSCLC). METHODS A total of 450 NSCLC patients who underwent tumor resection with a systemic mediastinal nodal dissection were retrospectively reviewed. p53 status and proliferative activity represented as prolifer...
متن کاملCutaneous metastases in non-small cell lung cancer.
To cite: McGrath RB, Flood SP, Casey R. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2014205752 DESCRIPTION A 61-year-old man presented with right pleuritic chest pain, 15 kg weight loss, shortness of breath and two painful scalp lesions (figure 1). He had a 40-pack a year smoking history with exposure to asbestos. Thoracocentesis of a right pleural effusion de...
متن کاملSystemic treatment of non-small cell lung cancer brain metastases
In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib or erlotinib, was an improvement in treatment of advanced NSCLC patients. EGFR mutations are prese...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Española de Enfermedades Digestivas
سال: 2012
ISSN: 1130-0108
DOI: 10.4321/s1130-01082012000800016